ABSTRACT
RESUMEN El virus de la hepatitis E tiene una amplia distribución a nivel mundial. Se presentaron dos casos clínicos en la provincia de Matanzas, con diagnóstico confirmado de hepatitis E mediante la determinación del ARN viral en heces fecales congeladas; a pesar de proceder de áreas de salud distantes, coincidieron en el mismo período de tiempo. El primero de ellos, una gestante asintomática diagnosticada fortuitamente a partir de elevación de enzimas hepáticas de citolisis. Evolucionó satisfactoriamente sin repercusión en su bienestar materno, trasmisión fetal, ni complicaciones perinatales. El segundo, una paciente portadora de síndrome metabólico, con evolución tórpida de su cuadro infeccioso viral, que la llevó a la insuficiencia hepática y a la muerte. Con estos casos se reflejó el amplio espectro de esta enfermedad en cuanto a formas clínicas de presentación y evolución. Se demostró que pueden ocurrir complicaciones en cualquier grupo poblacional, de ahí la importancia de considerarla en el diagnóstico diferencial de las enfermedades infecciosas hepáticas (AU).
ABSTRACT Hepatitis E virus is widely distributed around the world. Two clinical cases occurring in the province of Matanzas were presented, both with diagnosis of E hepatitis confirmed through viral RNA determination in frozen stool; although patients came from faraway health areas, they coincided in the same time period. The first patient, a pregnant asymptomatic woman, was incidentally diagnosed due to an increase of cytolysis liver enzymes. Her evolution was satisfactory without repercussion on maternal wellbeing, fetal transmission, nor perinatal complications. The second patient, a metabolic syndrome carrier, had torpid evolution of a viral infectious disease leading her to liver failure and death. These cases highlighted the wide range of this disease according to its clinical forms of presentation and evolution. It was showed that complications may occur in any population group, in consequence it is important to consider this disease when making the differential diagnosis of liver infectious diseases (AU).
Subject(s)
Humans , Male , Female , Clinical Evolution/classification , Hepatitis E/therapy , Hepatitis E/rehabilitation , Hepatitis E/epidemiology , Metabolic Syndrome/complications , Pregnant Women , Hepatic Insufficiency/diagnosis , Hepatic Insufficiency/therapyABSTRACT
Objective To study the SEN-V DNA in liver tissue from patients with non A to E hepatitis in Guangzhou area. Methods A set of primers according to the original sequence from GenBank were designed , and SEN-V DNA sequence was amplified by in situ-PCR in liver tissue. Results Two of 6 patients with non A to E hepatitis were found to be SEN-V-DNA positive in liver tissue. While 8 patients with HBV infection and 6 of other liver diseases including 2 of autoimmune liver disease, 1 of Dubin Johnson syndrome, 1 of fatty liver, 1 of the primary biliary cirrhosis and 1 of drug induced hepatitis were all SEN-V DNA negative. SEN-V DNA were mainly distributed in liver cell cytoplasm, partially in nucleus. There presented the phenomenon of cell fuse. SEN-V positive cells accounted for about 3%～10% of total cells.Conclusions SEN-V can be found in liver tissue of patients with non A to E hepatitis in south China. Maybe it can cause liver damage.
ABSTRACT
BACKGROUND: Hepatitis G virus(HGV) is known to be associated with non-A-E hepatitis but pathogenic relevance and mode of transmission are still unclear. In this study, we analyzed the prevalence and clinical implicati ons of HGV infection in patients on hemodialysis or being treated for hematologic disease, and healthy controls. METHODS: HGV RNA was identified in serum by reverse transcription-polymerase chain reaction(RT-PCR) with nested primers deduced from highly conserved area of the 5'-untranslated region. Other parenterally transmissible hepatitis viral markers(HBsAg and anti-HCV) and alanine aminotransferase(ALT), history of transfusion, duration of hemodialysis were assessed. RESULTS: HGV RNA was detected in 12.5%(8 of 64) of the patients on hemodialysis and in 24.1%(14 of 58) of the patients treated for hematologic disease, as compared with 0.8%(1 of 120) of healthy controls(P<0.05). HBsAg, anti-HCV, ALT level, rate of transfusion history and duration of hemodialysis were not significantly different between HGV-infected patients and non-HGV-infected patients. In patients treated for hematologic disease, sex was significantly different between HGV positive and negative groups. CONCLUSIONS: Patients on hemodialysis and being treated for hematologic disease have increased risk for HGV infection, but there was no clinical difference between HGV RNA positive and negative groups. HGV infection itself does not seem to be a frequent cause of liver disease in these patients. The clinical significance of long-term infection with HGV remains to be established.